DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: OCREVUS (ocrelizumab)
*****************************************************
#Post#: 2654--------------------------------------------------
(ECTRIMS) Early Ocrevus use in PPMS slows disability risk, inclu
ding risk of wheelchair reliance
By: agate Date: September 18, 2019, 1:44 am
---------------------------------------------------------
Hmm. No sooner has an announcement touting Mayzent (siponimod)
as helpful in delaying the need for a wheelchair for persons
with SPMS than it turns out that Ocrevus (ocrelizumab) can also
help to keep the dreaded wheelchair away--though the claim here
is for PPMS. From Multiple Sclerosis New Today (September 17,
2019)--"ECTRIMS 2019: Early Ocrevus Use in PPMS Slows Risk of
Disability, Including Risk of Wheelchair Reliance."
HTML https://multiplesclerosisnewstoday.com/news-posts/2019/09/06/ectrims2019-early-ocrevus-use-slows-disability-ppms-including-wheelchair-dependence/
#Post#: 2658--------------------------------------------------
Re: (ECTRIMS) Genentech reports Ocrevus living up to expectation
s
By: agate Date: September 19, 2019, 11:44 pm
---------------------------------------------------------
A more comprehensive overview of some of the Ocrevus material
presented at the ECTRIMS conference--again, from Multiple
Sclerosis News Today (September 19). The spokespeople are drug
company representatives. There have been 7 PML cases so far,
according to the article, but they are careful to point out
these were all "carryover cases":
HTML http://bit.ly/2kmpBr4
*****************************************************